Stock 4544 H.U. GROUP HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

H.U. Group Holdings, Inc. Stock

Equities

4544

JP3822000000

Healthcare Facilities & Services

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-09-20 am EDT 		5-day change 1st Jan Change
2,670.50 JPY -0.61% Intraday chart for H.U. Group Holdings, Inc. +1.87% +0.26%
Jul. 30 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer?S Disease CI
Jul. 26 H.U. Group Holdings, Inc. and Fujirebio Launches the Fully Automated Lumipulse G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu CI

Valuation: H.U. Group Holdings, Inc.

Capitalization 150B 1.05B P/E ratio 2025 *
32.5x
P/E ratio 2026 * 28.5x
Enterprise value 181B 1.26B EV / Sales 2025 *
0.77x
EV / Sales 2026 * 0.71x
Free-Float
98.83%
Yield 2025 *
4.59%
Yield 2026 * 4.59%
More valuation ratios * Estimated data

Chart: H.U. Group Holdings, Inc.

Dynamic Chart

Latest news: H.U. Group Holdings, Inc.

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer?S Disease CI
H.U. Group Holdings, Inc. and Fujirebio Launches the Fully Automated Lumipulse G GFAP Assay for Research Use Only and Further Strengthens its Neuro Test Menu CI
H.U. Group Secures Highest Rank at MSCI ESG Rating for Third Straight Year MT
H.U. Group Holdings, Inc. Announces Dividend for the Fiscal Year Ended March 31, 2024, Payable on May 28, 2024; Provides Dividend Guidance for the Second Quarter-End and Fiscal Year Ending March 31, 2025 CI
H.U. Group Holdings, Inc. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025 CI
H.U. Group Cuts Forecasts for Fiscal Year Ended March 31 MT
H.U. Group Holdings, Inc. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Executive Officer CI
H.U. Group Holdings, Inc. Announces Retirement of Atsuko Murakami as Chief Financial Officer CI
H.U Unit Fujirebio Diagnostics Partners Beckman Coulter in Neurodegenerative Diseases Field MT
Fujirebio and Beckman Coulter Expand Partnership to Develop Patient-Friendly, Blood-Based Neurodegenerative Disease Diagnostics CI
H.U. Group Holdings Inc. and Fujirebio Announces the Availability of the Lumipulse G pTau 217 Plasma Assay for the Fully Automated LUMIPULSE G Immunoassay Systems CI
Japanese Shares Rebound After Inflation Data, BoJ Rate Outlook MT
More news

Press Releases: H.U. Group Holdings, Inc.

Fujirebio launches the fully automated Lumipulse G GFAP assay for Research Use Only and further strengthens its Neuro test menu AQ
Recent DOJ Settlement With NextGen Highlights Continued Enforcement Focus On Electronic Health Records Technology Vendors AQ
H.U. Group Holdings Inc. - Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for Research Use Only AQ
Fujirebio expands its assay menu in the field of neurodegenerative diseases with the launch of the fully automated Lumipulse G NfL CSF and Lumipulse G NfL Blood tests AQ
DOJ Scrutiny Of EHR Vendors Continues With $45 Million Settlement For Alleged Kickbacks And False Claims AQ
More press releases

Quotes and Performance

1 day-0.61%
1 week+2.87%
Current month-0.32%
1 month+1.37%
3 months+13.71%
6 months+4.48%
Current year+0.26%
More quotes

Course Extremes

1 week
2 595.00
Extreme 2595
2 707.50
1 month
2 564.00
Extreme 2564
2 736.50
Current year
2 167.00
Extreme 2167
2 841.50
1 year
2 167.00
Extreme 2167
2 841.50
3 years
2 167.00
Extreme 2167
3 250.00
5 years
2 005.00
Extreme 2005
3 770.00
10 years
2 005.00
Extreme 2005
6 350.00
More quotes

Managers and Directors: H.U. Group Holdings, Inc.

Director TitleAgeSince
Shigekazu Takeuchi CEO
 Chief Executive Officer 70 16-05-31
Naoki Kitamura DFI
 Director of Finance/CFO 53 11-08-31
Toshihiko Shimizu CTO
 Chief Tech/Sci/R&D Officer 69 21-06-22
Manager TitleAgeSince
Ryoji Itoh BRD
 Director/Board Member 72 14-05-31
Naoki Kitamura DFI
 Director of Finance/CFO 53 11-08-31
Shigekazu Takeuchi CEO
 Chief Executive Officer 70 16-05-31
More insiders

ETFs: H.U. Group Holdings, Inc.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 IT & SERVICES, OTHERS ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 IT & SERVICES, OTHERS ETF - JPY
0.17% 15 M€ +12.06%
DAIWA ETF MSCI JAPAN ESG SELECT LEADERS INDEX ETF - JPY ETF Daiwa ETF MSCI Japan ESG Select Leaders Index ETF - JPY
0.05% 713 M€ +13.28%
More ETFs: H.U. Group Holdings, Inc.

Medical & Diagnostic Laboratories

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
H.U. GROUP HOLDINGS, INC. Stock H.U. Group Holdings, Inc.
-0.61%+2.87%+1.29%-17.19%1.07B
SONIC HEALTHCARE LIMITED Stock Sonic Healthcare Limited
-2.19%-2.70%-12.54%-36.92%8.79B
RADNET, INC. Stock RadNet, Inc.
+3.77%+3.58%+147.83%+143.41%5.15B
DR. LAL PATHLABS LIMITED Stock Dr. Lal PathLabs Limited
+0.32%-2.89%+35.97%-16.77%3.26B
SYNLAB AG Stock SYNLAB AG
+1.84%+1.28% - - 2.71B
NEOGENOMICS, INC. Stock NeoGenomics, Inc.
+1.98%+1.73%+29.05%-65.89%2.11B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD. Stock Guangzhou Kingmed Diagnostics Group Co., Ltd.
+1.94%-2.54%-57.11%-71.93%1.79B
FLEURY S.A. Stock Fleury S.A.
-0.42%-0.36%+13.21%-27.70%1.67B
METROPOLIS HEALTHCARE LIMITED Stock Metropolis Healthcare Limited
-0.36%-2.23%+42.17%-32.36%1.3B
JIANGXI RIMAG GROUP CO., LTD. Stock Jiangxi Rimag Group Co., Ltd.
-0.76%+28.33% - - 1.2B
Average +0.55%+2.65%+24.98%-15.67% 2.91B
Weighted average by Cap. +0.38%+1.20%+32.04%-0.62%
See all sector performances

Financials

2025 *2026 *
Net sales 244B 1.7B 253B 1.76B
Net income 4.72B 32.81M 5.27B 36.67M
Net Debt 37.97B 264M 29.12B 203M
More financial data * Estimated data

Company Profile

Logo H.U. Group Holdings, Inc.
H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.
Employees
5,295
Sector
Healthcare Facilities & Services
Calendar
2024-09-26 - Détachement de for dividende intermédiaire
More about the company

Quotes

Date Price Change Volume
24-09-20 2,670.50 ¥ -0.61% 370,300
24-09-19 2,687.00 ¥ +1.51% 172,100
24-09-18 2,647.00 ¥ -0.28% 185,100
24-09-17 2,654.50 ¥ +2.25% 343,200
24-09-13 2,596.00 ¥ -0.97% 205,600

Delayed Quote Japan Exchange, September 20, 2024 at 02:00 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
5
Last Close Price
2,687.00JPY
Average target price
2,388.00JPY
Spread / Average Target
-11.13%
Consensus
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 4544 Stock